CURE sat down with Dr. Kerry A. Rogers for an interview at the Hairy Cell Leukemia Foundation 2025 Conference, hosted in Bologna, Italy. We sat down with Dr. Kerry A. Rogers for an interview at the ...

Hairy cell leukaemia (HCL) remains an intriguing B‐cell malignancy defined by its distinctive “hairy” cytoplasmic projections and its unique pattern of bone marrow infiltration. Recent research has ...

Dr. Alessandro Gozzetti highlights fertility and reproductive health as often overlooked but vital aspects of survivorship in hairy cell leukemia. According to Dr. Alessandro Gozzetti, fertility and ...

HCL uniformly harbors a BRAF mutation that is not present in other B-cell malignancies. Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disorder that responds to several highly ...

Results from the largest report ever on young hairy cell leukemia (HCL) patients treated with standard chemotherapy — cladribine — are a mixed bag. On the one hand, a majority of the 83 patients, all ...

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): ...

Combination Therapy With Olaparib Plus Lenvatinib in a Patient With BRCA2-Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report The following represents disclosure ...